Figure 2.

Belimumab dosage forms in relation to development of at least 1 renal flare. The graphs in the upper panels (reverse Kaplan-Meier survival curves) delineate proportions of patients who developed a de novo renal flare over the course of the study period, stratified into patients who received (a) IV belimumab 1 mg/kg, (b) IV belimumab 10 mg/kg, or (c) SC belimumab 200 mg, and placebo-recipients. The lower panels (risk tables) show numbers of participants in the 2 groups over time, decreasing due to documentation of at least 1 renal flare. IV, intravenous; SC, subcutaneous.